An2 Therapeutics Stock Market Value
| ANTX Stock | USD 1.03 0.03 2.83% |
| Symbol | AN2 |
AN2 Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AN2 Therapeutics. If investors know AN2 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AN2 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Return On Assets (0.43) | Return On Equity (0.69) |
The market value of AN2 Therapeutics is measured differently than its book value, which is the value of AN2 that is recorded on the company's balance sheet. Investors also form their own opinion of AN2 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is AN2 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AN2 Therapeutics' market value can be influenced by many factors that don't directly affect AN2 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AN2 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AN2 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AN2 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
AN2 Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to AN2 Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of AN2 Therapeutics.
| 10/28/2022 |
| 10/17/2024 |
If you would invest 0.00 in AN2 Therapeutics on October 28, 2022 and sell it all today you would earn a total of 0.00 from holding AN2 Therapeutics or generate 0.0% return on investment in AN2 Therapeutics over 720 days. AN2 Therapeutics is related to or competes with Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, Rezolute, Anebulo Pharmaceuticals, Mineralys Therapeutics,, and Molecular Partners. AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, ... More
AN2 Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure AN2 Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess AN2 Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 69.81 | |||
| Value At Risk | (4.85) | |||
| Potential Upside | 5.83 |
AN2 Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for AN2 Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as AN2 Therapeutics' standard deviation. In reality, there are many statistical measures that can use AN2 Therapeutics historical prices to predict the future AN2 Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (1.59) | |||
| Treynor Ratio | (0.68) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of AN2 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
AN2 Therapeutics Backtested Returns
AN2 Therapeutics retains Efficiency (Sharpe Ratio) of -0.12, which signifies that the company had a -0.12% return per unit of price deviation over the last 3 months. AN2 Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm AN2 Therapeutics' Information Ratio of (0.12), variance of 64.45, and Market Risk Adjusted Performance of (0.67) to double-check the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 1.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AN2 Therapeutics will likely underperform. At this point, AN2 Therapeutics has a negative expected return of -0.96%. Please make sure to confirm AN2 Therapeutics' total risk alpha, as well as the relationship between the kurtosis and price action indicator , to decide if AN2 Therapeutics performance from the past will be repeated sooner or later.
Auto-correlation | 0.18 |
Very weak predictability
AN2 Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between AN2 Therapeutics time series from 28th of October 2022 to 23rd of October 2023 and 23rd of October 2023 to 17th of October 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of AN2 Therapeutics price movement. The serial correlation of 0.18 indicates that over 18.0% of current AN2 Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.18 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 57.13 |
AN2 Therapeutics lagged returns against current returns
Autocorrelation, which is AN2 Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting AN2 Therapeutics' stock expected returns. We can calculate the autocorrelation of AN2 Therapeutics returns to help us make a trade decision. For example, suppose you find that AN2 Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
AN2 Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If AN2 Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if AN2 Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in AN2 Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
AN2 Therapeutics Lagged Returns
When evaluating AN2 Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of AN2 Therapeutics stock have on its future price. AN2 Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, AN2 Therapeutics autocorrelation shows the relationship between AN2 Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in AN2 Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.